| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JBMR.2858 |
| P698 | PubMed publication ID | 27093323 |
| P50 | author | Diana Ovejero Crespo | Q86894757 |
| P2093 | author name string | Michael T Collins | |
| Rachel I Gafni | |||
| P2860 | cites work | Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice | Q46295463 |
| Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D. | Q46761922 | ||
| Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia | Q47871507 | ||
| X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. | Q51655584 | ||
| Healing of bone lesions with 1,25-dihydroxyvitamin D3 in the young X-linked hypophosphatemic male mouse. | Q54512903 | ||
| Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse | Q54520940 | ||
| Bone Response to Phosphate Salts, Ergocalciferol, and Calcitriol in Hypophosphatemic Vitamin D-Resistant Rickets | Q54546729 | ||
| X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry | Q58086003 | ||
| Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 | Q24290481 | ||
| FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis | Q24319751 | ||
| Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations | Q24595718 | ||
| FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization | Q28177435 | ||
| Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
| Long-term follow-up of patients with hypoparathyroidism | Q28276548 | ||
| Effects of therapy in X-linked hypophosphatemic rickets | Q28321935 | ||
| X linked hypophosphataemia: treatment, height gain, and nephrocalcinosis | Q30495036 | ||
| FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting | Q34227442 | ||
| Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets | Q35044977 | ||
| A clinician's guide to X-linked hypophosphatemia | Q35167526 | ||
| Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. | Q35728669 | ||
| A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells | Q35783146 | ||
| Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. | Q35829300 | ||
| Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites | Q36288312 | ||
| CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders | Q36515176 | ||
| Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. | Q36649088 | ||
| Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets | Q36662050 | ||
| 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression. | Q36889321 | ||
| Evaluation of a Role for 1,25-Dihydroxyvitamin D3 in the Pathogenesis and Treatment of X-linked Hypophosphatemic Rickets and Osteomalacia | Q37024792 | ||
| Role of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption in rats with a normal vitamin D supply | Q37046700 | ||
| Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia | Q37406418 | ||
| Tumor localization and biochemical response to cure in tumor-induced osteomalacia. | Q37509096 | ||
| The PTH-Vitamin D-FGF23 axis | Q38571195 | ||
| An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. | Q40482177 | ||
| Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets | Q41555789 | ||
| Cinacalcet in the management of tumor-induced osteomalacia | Q42163969 | ||
| Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. | Q42493065 | ||
| X-linked hypophosphatemia: normal renal function despite medullary nephrocalcinosis 25 years after transient vitamin D2-induced renal azotemia | Q42545654 | ||
| Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia | Q44414604 | ||
| Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. | Q45020373 | ||
| FGF-23 is elevated by chronic hyperphosphatemia | Q45050609 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 925-928 | |
| P577 | publication date | 2016-05-01 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | 1,25-Dihydroxyvitamin D as Monotherapy for XLH: Back to the Future? | |
| P478 | volume | 31 |
Search more.